Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 7 )

2018 ( 74 )

2017 ( 63 )

2016 ( 93 )

Custom range...

Search Results: 1 - 10 of 27407 matches for " Robert Grimer "
All listed articles are free for downloading (OA Articles)
Page 1 /27407
Display every page Item
Angioleiomyoma: A Rare Cause of Fixed Flexion Contracture of the Elbow
Asterios Dramis,Robert J. Grimer
Sarcoma , 2006, DOI: 10.1155/srcm/2006/93569
Abstract: We describe an unusual case of a patient presented with a painless fixed flexion contracture of the elbow due to an angioleiomyoma. This benign smooth muscle tumour should be considered in the differential diagnosis of flexion contractures of the elbow.
Quality of Life in Survivors of a Primary Bone Tumour:A Systematic Review
Christine Eiser,Robert J. Grimer
Sarcoma , 1999, DOI: 10.1080/13577149977622
Recurrent Episodic Foot-Drop Following Surgery to the Thigh
Srinivas Maiya,Simon Tan,Robert J. Grimer
Sarcoma , 2000, DOI: 10.1155/2000/949842
Abstract: Subject. We present the case history of a 47-year-old lady who, 10 months following excision of a soft tissue sarcoma from the left thigh, was struck with recurrent episodes of foot drop.
How to Remove a Dumbbell Tumour of the Sciatic Notch
Matthew P. Revell,Robert J. Grimer
Sarcoma , 2000, DOI: 10.1155/s1357714x00000104
Abstract: Purpose.To look at a method for treating soft tissue sarcoma of the retroperitoneal area.
‘He Never Liked Sport Anyway’ - Mother's Views of Young People Coping With a Bone Tumour in the Lower Limb
Emily A. Earle,Christine Eiser,Robert Grimer
Sarcoma , 2005, DOI: 10.1080/13577140500043823
Abstract: Purpose: Treatment for a bone tumour can compromise quality of life (QOL), especially for young patients. We used qualitative methods to assess mothers' views of patients' experiences and their coping strategies at approximately 6 months after diagnosis (T1: n=12) and 12–18 months later (T2: n=11).
Bilateral Endoprosthetic Replacements of the Proximal Femur
Athanasios F. Foukas,Robert J. Grimer
Sarcoma , 1998, DOI: 10.1080/13577149878163
Guidelines for the Management of Soft Tissue Sarcomas
Robert Grimer,Ian Judson,David Peake,Beatrice Seddon
Sarcoma , 2010, DOI: 10.1155/2010/506182
Abstract: These guidelines were drawn up following a consensus meeting of UK sarcoma specialists convened under the auspices of the British Sarcoma Group and are intended to provide a framework for the multidisciplinary care of patients with soft tissue sarcomas. The guidelines published by the European Society of Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) were used as the basis for discussion and adapted according to UK clinical practice and local requirements. Note was also taken of the National Institute for Health and Clinical Excellence (NICE) improving outcomes guidance (IOG) for people with sarcoma and existing technology appraisals. The guidelines are not intended to challenge NICE guidance but discrepancies may exist where current guidance does not reflect an international standard of care owing to the ever-evolving nature of cancer treatment. It is acknowledged that these guidelines will require updating on a regular basis. An appendix lists the key recommendations which are summarised below. Any patient with a suspected soft tissue sarcoma should be referred to a diagnostic centre and managed by a specialist sarcoma multidisciplinary team. Surgical excision followed by post operative radiotherapy is the standard management of high grade limb sarcomas although occasionally amputation remains the only option. Pre-operative treatment with chemotherapy or radiotherapy should be considered for patients with borderline resectable tumours. Isolated limb perfusion may permit limb salvage in some cases where amputation is the only other option. Adjuvant chemotherapy is not routinely recommended but may be considered in certain specific situations. Regular follow up is recommended to assess local control and the development of metastatic disease. Single agent doxorubicin is the standard first line therapy for metastatic disease. Ifosfamide is an alternative if anthracyclines are contraindicated. Combination therapy may be considered in individual patients. Second line agents include ifosfamide, dacarbazine, trabectedin and the combination of gemcitabine
The Toronto Extremity Salvage Score in Unoperated Controls: An Age, Gender, and Country Comparison
Mark Clayer,Simon Doyle,Nicole Sangha,Robert Grimer
Sarcoma , 2012, DOI: 10.1155/2012/717213
Abstract: The Toronto Extremity Salvage Score (TESS) is widely used for the functional assessment of patients following surgery for musculoskeletal tumours. The aim of this study was to determine if there are gender and/or age-specific changes, unrelated to surgery, that may influence this score and the appropriateness of the questions. The TESS for lower limb was carried out in two different countries to see if there was variation between them. There were no statistically significant differences between the scores obtained between the respondents from Australia or Britain either in total or between the corresponding age groups. There were statistically significant differences in the TESS obtained between age groups with a lower score at older age groups but there was no difference between the sexes. Patients in the age group 70
Comparison of the Outcome of Conventional Osteosarcoma at Two Specialist International Orthopaedic Oncology Centres
Samuel Ford,Adnan Saithna,Robert J. Grimer,Piero Picci
Sarcoma , 2004, DOI: 10.1080/13577140410001679202
Abstract: Objective: To determine the prognostic value of patient and treatment parameters in osteosarcoma, and whether these are equally important across international boundaries.
Prognostic and Survival Factors in Myxofibrosarcomas
Varun Dewan,Anna Darbyshire,Vaiyapuri Sumathi,Lee Jeys,Robert Grimer
Sarcoma , 2012, DOI: 10.1155/2012/830879
Abstract: Aim. Our study aimed to determine prognostic factors for survival and recurrence in myxofibrosarcomas based on the experience of a single institution. Methods. Patients who had been diagnosed with a myxofibrosarcoma were identified from our database. Survival and recurrence were evaluated with Kaplan Meier survival curves for univariate and cox regression for multivariate analysis. Results. 174 patients with a diagnosis of myxofibrosarcoma were identified. Two patients were excluded due to incomplete information, leaving 172 patients with a mean age of 67 years. Surgery was undertaken in all but 6 patients. Five-year survival was better for myxofibrosarcomas when compared to other soft tissue sarcomas (63% versus 57%). Size, grade of tumour, age, and metastases were all found to be prognostic factors. Local recurrence occurred in 29 patients (17%) with an overall risk of 15% at 5 years. Previous inadvertent excision significantly raised this risk to 45%. Wide surgical margins and depth of tumour, however, had no impact on recurrence. Conclusion. Factors previously identified as prognostic did not demonstrate such a relationship in our study, highlighting the unpredictable nature of myxofibrosarcomas. Future treatment may lie in developing an understanding molecular basis of the tumour and directing therapies accordingly.
Page 1 /27407
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.